Vaxiion's proprietary bacterial strains are each designed with inducible minicell-production phenotypes to ensure reliable and reproducible production.
Targeted Drug Delivery using rBMCs
Engineering in specific targeting modalities can be accomplished by a variety of means including the surface expression of recombinant targeting molecules including single chain antibody fragments and bacterial adhesins/invasins. In another approach, Vaxiion has generated an entire rBMC platform system capable of binding and displaying antibodies in the proper orientation by simply mixing rBMCs with the antibody of choice. Covalent attachment methods including chemical cross-linking are also amenable and scalable with rBMCs.
Vaxiion's Recombinant Bacterial Minicell Platform
Because rBMCs incorporate anything present in the parental bacterial strain with the exception of the chromosome, they can be easily modified to contain molecules produced recombinantly from the parental cells before induction of the rBMC production phenotype. Such molecules include recombinant proteins (including protein toxin payloads and rBMC-surface localized cancer cell targeting molecules), expression plasmids, and various silencing RNA molecules - making for a highly versatile "self assembling" delivery technology. Adding to these capabilities, Vaxiion's rBMCs can be loaded with high concentrations of small molecule drugs following purification.